nifedipine has been researched along with midazolam in 62 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.61) | 18.7374 |
1990's | 10 (16.13) | 18.2507 |
2000's | 23 (37.10) | 29.6817 |
2010's | 27 (43.55) | 24.3611 |
2020's | 1 (1.61) | 2.80 |
Authors | Studies |
---|---|
Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
Topliss, JG; Yoshida, F | 1 |
Katoh, M; Nakajima, M; Yamazaki, H; Yokoi, T | 1 |
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Evans, CA; Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Bonomo, F; Motta, P; Pagliarusco, S; Pellegatti, M; Pons, N | 1 |
Bass, JY; Caravella, JA; Chen, L; Creech, KL; Deaton, DN; Madauss, KP; Marr, HB; McFadyen, RB; Miller, AB; Mills, WY; Navas, F; Parks, DJ; Smalley, TL; Spearing, PK; Todd, D; Williams, SP; Wisely, GB | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chan, KH; Hseu, SS; Lee, TY; Lui, PW | 1 |
Hertz, L; Stolzenburg, JU; Subbarao, KV | 1 |
Ring, BJ; Wrighton, SA | 1 |
Watkins, PB | 1 |
Code, WE; Hertz, L; Zhao, Z | 1 |
Laufen, H; Scharpf, F; Yeates, RA; Zimmermann, T | 1 |
Kanmura, Y; Yamaguchi, S; Yoshimura, N | 1 |
Asahi, S; Gillam, EM; Guengerich, FP; Nakajima, M; Nakamura, M; Shimada, N; Shimada, T; Yamazaki, H; Yokoi, T | 1 |
Crespi, CL; Davitt, CM; Hu, M; Huang, SM; Li, Y; Penman, BW; Thummel, K | 1 |
Atkins, WM; Liu, N; Lu, AY; Newton, DJ; Wang, RW | 1 |
Blanchard, AP; Crespi, CL; Dandeneau, AA; Erve, JC; Miller, VP; Stresser, DM; Turner, SD | 1 |
Emoto, C; Iketaki, H; Nakajima, M; Satoh, T; Shimada, N; Shimizu, R; Suzuki, S; Yamasaki, S; Yamazaki, H; Yokoi, T | 1 |
Cantrell, VE; Eckstein, J; Hall, SD; Hamman, MA; Jones, DR; Ring, BJ; Ruterbories, K; Williams, JA; Wrighton, SA | 1 |
Blain, PG; Daly, AK; Leathart, JB; Mutch, E; Williams, FM | 1 |
Greenblatt, DJ; Patki, KC; Von Moltke, LL | 1 |
Clarke, SE; Galetin, A; Houston, JB | 1 |
Cook, CS; Fitzloff, JF; Shen, L | 1 |
Galetin, A; Hallifax, D; Houston, JB; Ito, K | 1 |
Booth-Genthe, C; Carr, B; Fang, Y; Lu, P; Norcross, R; Rodrigues, AD; Rushmore, T; Shou, M | 1 |
Nakamura, K; Okazaki, O; Okudaira, N; Sudo, K; Watanabe, A | 1 |
Fujita, Y; Guengerich, FP; Horiuchi, R; Miyazaki, M; Nakamura, K; Yamamoto, K | 1 |
Fukuzaki, K; Kohara, S; Matsushita, A; Murayama, N; Nagata, R; Osada, N; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
Foti, RS; Rock, DA; Wahlstrom, JL; Wienkers, LC | 1 |
Aoki, M; Haga, M; Hayashi, M; Nishigaki, R; Okudaira, K | 1 |
Adams, LM; Fernandes, SA; Fina, P; Fiore, M; Johnson, BM; Pagliarusco, S; Peroni, M; Zamuner, S | 1 |
Court, MH; Duan, SX; Greenblatt, DJ; Harmatz, JS; Parent, SJ; Venkatakrishnan, K; von Moltke, LL; Zhao, Y | 1 |
Hayashi, M; Shou, M; Skiles, GL; Xu, Y; Zhou, Y | 1 |
Ali Khan, MA; Hasan, N; Sabir, MS | 1 |
Aiba, T; Kajikawa, N; Kawasaki, H; Kurosaki, Y; Kusaba, J | 1 |
Annes, WF; Ayan-Oshodi, MA; Brown, T; de la Peña, A; Friedrich, S; Hall, SD; Lowe, SL; Willis, BA; Wise, SD; Zhang, W | 1 |
Cao, Y; Ge, G; Hong, JY; Liu, Y; Wu, J; Yang, L; Zhang, Y; Zhu, L | 1 |
Baneyx, G; Iliadis, A; Lavé, T; Meille, C; Parrott, N | 1 |
Ishigai, M; Kato, M; Mitsui, T; Miyake, T; Nagao, S; Nemoto, T; Ogawa, K; Yamada, H | 1 |
Kosugi, Y; Takahashi, J | 1 |
Lee, E; Liu, KH; Shon, JC | 1 |
Inoue, T; Ishii, S; Nakanishi, K; Sasaki, E; Uehara, S; Uno, Y; Yamazaki, H | 1 |
Cao, YF; Fang, ZZ; Gonzalez, FJ; Liu, YZ; Sun, HZ; Sun, T; Wu, JJ; Yang, K; Yin, J; Zhao, J; Zhu, ZT | 1 |
Akiyoshi, T; Imaoka, A; Ishikawa, Y; Ohtani, H | 1 |
Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I | 1 |
Kondo, S; Miyake, M | 1 |
Morikuni, S; Murayama, N; Noda, Y; Uno, Y; Yamazaki, H | 1 |
2 review(s) available for nifedipine and midazolam
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Noninvasive tests of CYP3A enzymes.
Topics: Animals; Breath Tests; Cytochrome P-450 Enzyme System; Dapsone; Erythromycin; Humans; Hydrocortisone; Lidocaine; Liver; Midazolam; Nifedipine | 1994 |
3 trial(s) available for nifedipine and midazolam
Article | Year |
---|---|
Midazolam as an induction agent for thoracotomy in comparison with diazepam with or without nifedipine.
Topics: Adult; Aged; Anesthetics; Clinical Trials as Topic; Diazepam; Female; Humans; Male; Midazolam; Middle Aged; Nifedipine; Preanesthetic Medication; Random Allocation; Thoracotomy | 1988 |
Screening for cytochrome P450 3A in man: studies with midazolam and nifedipine.
Topics: Adult; Area Under Curve; Biotransformation; Calcium Channel Blockers; Chromatography, Gas; Cytochrome P-450 CYP2E1; Female; GABA Modulators; Humans; Male; Midazolam; Middle Aged; Nifedipine | 1996 |
The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Topics: Administration, Oral; Adult; Aged; Alanine; Amyloid Precursor Protein Secretases; Area Under Curve; Azepines; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Half-Life; Hepatocytes; Humans; Hydroxylation; Ketoconazole; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Models, Biological; Nifedipine; Testosterone; Young Adult | 2012 |
57 other study(ies) available for nifedipine and midazolam
Article | Year |
---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Digoxin; Enzyme Inhibitors; GABA Modulators; Gonadal Steroid Hormones; Humans; LLC-PK1 Cells; Midazolam; Mixed Function Oxygenases; Nifedipine; Phthalazines; Swine; Testosterone | 2001 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
Topics: Animals; Biometry; Dogs; Drug Evaluation, Preclinical; Haloperidol; Haplorhini; Humans; Injections, Intravenous; Liver; Liver Circulation; Metabolic Clearance Rate; Mifepristone; Molecular Structure; Molecular Weight; Rats; Reproducibility of Results | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
Topics: Adult; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Molecular; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Piperazines; Piperidines; Recombinant Proteins; Young Adult | 2011 |
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
Topics: Animals; Binding Sites; Blood Glucose; Crystallography, X-Ray; Diabetes Mellitus, Experimental; Dogs; Fluorescence Resonance Energy Transfer; Humans; Isoxazoles; Ligands; Mice; Molecular Conformation; Naphthalenes; Protein Structure, Tertiary; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Weight Gain | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Pharmacological characteristics of potassium-induced, glycogenolysis in astrocytes.
Topics: Animals; Astrocytes; Cells, Cultured; Cyclic AMP; Glycogen; Mice; Mice, Inbred Strains; Midazolam; Nifedipine; Potassium; Time Factors | 1995 |
Grapefruit juice interactions with drugs.
Topics: Beverages; Caffeine; Citrus; Cyclosporine; Estrogens; Felodipine; Food-Drug Interactions; Humans; Midazolam; Nifedipine; Terfenadine | 1995 |
Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.
Topics: Chromatography, High Pressure Liquid; Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Nizatidine | 1994 |
Effects of benzodiazepines on potassium-induced increase in free cytosolic calcium concentration in astrocytes: interactions with nifedipine and the peripheral-type benzodiazepine antagonist PK 11195.
Topics: Animals; Anti-Anxiety Agents; Astrocytes; Calcium; Calcium Channel Blockers; Cytosol; Diazepam; Drug Interactions; Isoquinolines; Membrane Potentials; Mice; Mice, Inbred Strains; Midazolam; Nifedipine; Potassium | 1996 |
Effects of midazolam on contractions in smooth muscle of the rabbit mesenteric artery.
Topics: Adrenergic alpha-Agonists; Anesthetics, Intravenous; Animals; Caffeine; Calcium Channel Blockers; Dose-Response Relationship, Drug; Hypnotics and Sedatives; In Vitro Techniques; Male; Mesenteric Arteries; Midazolam; Muscle Contraction; Muscle, Smooth, Vascular; Nifedipine; Norepinephrine; Potassium; Rabbits | 1997 |
Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
Topics: Anesthetics, Intravenous; Bacteria; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Escherichia coli; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Membranes; Midazolam; Mixed Function Oxygenases; NADPH-Ferrihemoprotein Reductase; Nifedipine; Oxidation-Reduction; Recombinant Proteins; Testosterone | 1999 |
Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase.
Topics: Anticoagulants; Antineoplastic Agents, Hormonal; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Carcinogens; Cell Division; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diuretics, Osmotic; GABA Modulators; Gene Expression Regulation, Enzymologic; Genetic Vectors; Humans; Indoles; Mammary Tumor Virus, Mouse; Mannitol; Microscopy, Electron; Microsomes; Midazolam; Mixed Function Oxygenases; Nifedipine; Oxidoreductases; Propranolol; Pyridines; Sympatholytics; Testosterone; Tetradecanoylphorbol Acetate; Transfection; Tritium; Warfarin | 1999 |
Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxylation; Kinetics; Microsomes; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Nifedipine; Recombinant Proteins; Substrate Specificity; Terfenadine; Testosterone | 2000 |
Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.
Topics: Algorithms; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluorescent Dyes; GABA Modulators; Humans; In Vitro Techniques; Kinetics; Mass Spectrometry; Midazolam; Mixed Function Oxygenases; Nifedipine; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Testosterone | 2000 |
Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
Topics: Animals; Benzoflavones; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; GABA Modulators; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Intestines; Kinetics; Mice; Microsomes; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Nifedipine; Oxygen; Protein Binding; Steroid Hydroxylases; Terfenadine; Testosterone; Vasodilator Agents | 2001 |
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Topics: Alprazolam; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clarithromycin; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Diltiazem; Estradiol; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Midazolam; Nifedipine; Tamoxifen; Testosterone; Triazolam | 2002 |
Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Humans; Insecta; Mephenytoin; Microsomes, Liver; Midazolam; NADP; Nifedipine; Nitrophenols; Paclitaxel; Paraoxon; Parathion; Testosterone | 2003 |
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Recombinant Proteins; Testosterone; Triazolam | 2003 |
Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
Topics: Binding Sites; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Felodipine; Humans; Kinetics; Midazolam; Models, Biological; Nifedipine; Substrate Specificity; Testosterone; Tumor Cells, Cultured | 2003 |
Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Topics: Aryl Hydrocarbon Hydroxylases; Binding Sites; Calcium Channel Blockers; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; In Vitro Techniques; Kinetics; Mass Spectrometry; Microsomes, Liver; Midazolam; Nifedipine; Oxidoreductases, N-Demethylating; Stereoisomerism; Testosterone; Verapamil | 2004 |
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
Topics: Algorithms; Anti-Arrhythmia Agents; Area Under Curve; Azoles; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Forecasting; Humans; Hypnotics and Sedatives; In Vitro Techniques; Kinetics; Microsomes; Midazolam; Nifedipine; Quinidine; Substrate Specificity; Testosterone | 2005 |
Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes.
Topics: Amino Acid Sequence; Animals; Baculoviridae; Base Sequence; Blotting, Western; Cell Line; Cloning, Molecular; Coumarins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Humans; Ketoconazole; Kinetics; Liver; Macaca mulatta; Microsomes, Liver; Midazolam; Molecular Sequence Data; Nifedipine; Recombinant Proteins; Sequence Analysis, DNA; Spodoptera; Substrate Specificity; Testosterone | 2006 |
Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Topics: Animals; Automation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Midazolam; Models, Biological; Molecular Structure; Nifedipine; Protein Binding; Reproducibility of Results; Risk Assessment; Structure-Activity Relationship; Testosterone | 2007 |
Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Topics: Alleles; Catalysis; Cytochrome P-450 CYP3A; Enzyme Activation; Humans; Isoenzymes; Microsomes, Liver; Midazolam; Nifedipine; Oxidation-Reduction; Recombinant Proteins; Substrate Specificity; Testosterone | 2008 |
Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques.
Topics: Animals; Asia, Southeastern; China; Cytochrome P-450 CYP3A; DNA; Genetic Variation; Humans; Introns; Isoenzymes; Macaca fascicularis; Macaca mulatta; Midazolam; Nifedipine; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2010 |
Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
Topics: Algorithms; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Felodipine; Microsomes, Liver; Midazolam; Molecular Structure; Nifedipine; Quinidine; Substrate Specificity; Testosterone | 2010 |
Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine.
Topics: Animals; Drug Administration Routes; Drug Evaluation, Preclinical; Forecasting; In Vitro Techniques; Lidocaine; Lung; Male; Microsomes; Microsomes, Liver; Midazolam; Nifedipine; Rats; Rats, Wistar | 2010 |
Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine.
Topics: Adult; Calcium Channel Blockers; Cohort Studies; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Neurokinin-1 Receptor Antagonists; Nifedipine; Piperazines; Piperidines; Young Adult | 2010 |
Mechanism of cytochrome P450-3A inhibition by ketoconazole.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Inhibitory Concentration 50; Ketoconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Nifedipine; Testosterone; Triazolam; Young Adult | 2011 |
Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
Topics: Area Under Curve; Carbamazepine; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Hepatocytes; Humans; Midazolam; Nifedipine; Phenobarbital; Rifampin; Simvastatin; Substrate Specificity | 2011 |
Hypertensive encephalopathy: a rare presentation of Williams-Beuren Syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Child, Preschool; Diuretics; Enalapril; Furosemide; GABA Modulators; Humans; Hypertensive Encephalopathy; Male; Midazolam; Nifedipine; Williams Syndrome | 2011 |
Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure.
Topics: Acute Kidney Injury; Animals; Cytochrome P-450 CYP3A; Glycerol; Male; Microsomes, Liver; Midazolam; Nifedipine; Rats; Rats, Wistar; Rifabutin | 2012 |
Deoxyschizandrin, a naturally occurring lignan, is a specific probe substrate of human cytochrome P450 3A.
Topics: Animals; Biotransformation; Cyclooctanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Kinetics; Lignans; Male; Microsomes, Liver; Midazolam; Nifedipine; Oxidation-Reduction; Polycyclic Compounds; Rats; Rats, Wistar; Testosterone | 2014 |
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Topics: Alfentanil; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Hepatocytes; Humans; Midazolam; Models, Biological; Nifedipine; Rifampin; Tissue Distribution; Triazolam | 2014 |
A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes.
Topics: Alprazolam; Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Felodipine; Humans; Male; Mice; Mice, Transgenic; Microsomes, Liver; Midazolam; Nifedipine; Nitrendipine; Quinidine | 2014 |
Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
Topics: Administration, Oral; Alkynes; Animals; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Interactions; Haplorhini; Humans; Hydroxylation; Male; Microsomes, Liver; Midazolam; Nifedipine; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Species Specificity; Substrate Specificity; Testosterone | 2015 |
Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Discovery; Drug Interactions; Humans; Microsomes, Liver; Midazolam; Nifedipine; Substrate Specificity; Testosterone | 2016 |
Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone.
Topics: Adolescent; Adult; Aged; Alprazolam; Animals; Callithrix; Cytochrome P-450 CYP3A; Female; Humans; Intestine, Small; Liver; Macaca fascicularis; Male; Microsomes; Midazolam; Middle Aged; Multigene Family; Nifedipine; Pharmaceutical Preparations; Phylogeny; Sequence Alignment; Sequence Homology, Amino Acid; Species Specificity; Testosterone; Young Adult | 2017 |
Inhibition of human CYP3A4 and CYP3A5 enzymes by gomisin C and gomisin G, two lignan analogs derived from Schisandra chinensis.
Topics: Cyclooctanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dioxoles; Herb-Drug Interactions; Humans; Hydroxylation; Lignans; Midazolam; Molecular Structure; Nifedipine; Oxidation-Reduction; Schisandra; Testosterone | 2017 |
Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.
Topics: Anti-Bacterial Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Kinetics; Midazolam; Nifedipine; Testosterone | 2017 |
A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Topics: Caffeine; Cytochrome P-450 Enzyme System; Diazepam; Female; Granisetron; Humans; Metoprolol; Metronidazole; Midazolam; Models, Biological; Nifedipine; Ondansetron; Pharmaceutical Preparations; Pregnancy | 2018 |
Simultaneous Prediction of Intestinal Absorption and Metabolism Using the Mini-Ussing Chamber System.
Topics: Animals; Drug Delivery Systems; Intestinal Absorption; Intestinal Mucosa; Ketoconazole; Male; Midazolam; Nifedipine; Permeability; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley | 2019 |
Liver microsomal cytochrome P450 3A-dependent drug oxidation activities in individual dogs.
Topics: Alprazolam; Animals; Cytochrome P-450 CYP3A; Dogs; Estradiol; Hydroxylation; Liver; Microsomes, Liver; Midazolam; Nifedipine; Rats; RNA, Messenger | 2023 |